Adverse effects of multidrug therapy in leprosy patients: A five-year survey at a Health Center of the Federal University of Uberlândia;Efeitos adversos da poliquimioterapia em pacientes com hanseníase: Um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 35, Issue 5, 2002, Pages 453-460

  Bernades Goulart, Isabela Maria ^a,b   Leonel Arbex, Guilherme ^a   Hubaide Carneiro, Marcus ^a   Scalia Rodrigues, Mariana ^a   Gadia, Rafael ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b Campus Umuarama ^*  (Brazil)

Author keywords

Adhesion to treatment; Adverse effects; Hansen's disease; Multidrug therapy

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DYSPNEA; ERYTHEMA; EXFOLIATIVE DERMATITIS; FACE EDEMA; FEMALE; FEVER; GASTRITIS; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; INFANT; INSOMNIA; KIDNEY COLIC; LEPROSY; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PRURITUS; SKIN ALLERGY;

STAPHYLOCOCCUS PHAGE 187;

EID: 0036452568     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822002000500005     Document Type: Article

References (25)

1. Brasil MTLRF, Opromolla DWA, Marzliak MLC, Nogueira W. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. International Journal of Leprosy 64:97-103, 1996.
2. Browne SG, Hogerzeil LM. "B663" in the treatment of leprosy: Preliminary report of a pilot trial. Leprosy Review 33:6-10, 1962.
3. Ferreira MLC, Vieira LMM, Teixeira OMJ, Matos HJ, Nery JCA, Pereira RMO. Hansenfase: Perfil socioeconômico de uma populaçâo ambulatorial submetida à PQT. Hansenologia Internationalis 22;103, 1997.
4. Fundaçâo Nacional de Saúde. Hanseníase no Brasil - Progressos e Dificuldades em Relaçào à Eliminaçâo. SPS/DGSP/CENEPI/FNS. Ministério da Saúde, Brasil, 1998.
5. Fundaçâo Nacional de Saúde. Manual de Procedimentos Para a Execuçâo das Atividades de Controle da Hanseniase. SPS/ DGPE/ATDS. Ministério da Saúde, Brasil, 1999.
6. Gallo MEN, Nery JAC, Garcia CC. Intercorrências pelas drogas utilizadas nos esquemas poliquimioterápicos em hanseníase. Hansenologia Internationalis 20: 46-50, 1995.
7. Goulart IMB, Lopes VR, Massuda D. Fatores que interferem no controle da hanseníase na rede básica de assistência à saúde. Hansenologia Internationalis 16:7-15, 1991.
8. Hastings RC. Leprosy. Churchill Livingstone, New York, Edinburgh, London, Melbourne p. 331, 1985.
9. Jopling WH. References to "side-effects of antileprosy drugs in common use". Leprosy Review 56:61-70, 1985.
10. Jopling WH. Side effects of antileprosy drugs in common use. Leprosy Review 54:261-270, 1983.
11. Lau G. A fatal case of drug-induced multi-organ damage in a patient with Hansen's disease: Dapsone syndrome or rifampin toxicity? Forensics Science International 73:109-115, 1995.
12. o Ediçâo, p.167. 1997.
13. Noorden SK. The epidemiology of leprosy. In: Hastings RC (eds) Leprosy New York: Churchill Livingstone Inc, p.15-30, 1985.
14. th International Congress of Leprology 2:346-355, 1963.
15. Opromolla DVA. As reações adversas à rifampicina com especial referência à insuficiência renal aguda. Hansenologia Internationalis 17: 1-4, 1992.
16. Opromolla DVA. Terapêutica da hanseníase, Medicina Ribeirão Preto 30:345-350, 1997.
17. Papaordanou PMO, Branchini MLM, Gonçales Jr FL, Aoki FH, Boccato RSBS, Ramos MC, Pedro RJ. Efeito Adverso do Uso Intermitente de Rifampicina para Tratamento de Hanseníase. Revista do Instituto de Medicina Tropical de São Paulo 30:383-386, 1988.
18. Pfaltzgraff RE, Bryceson A. Clinical leprosy. In: Hastings RC. Leprosy. New York: Churchill Livingstone Inc, p.134-136, 1985.
19. Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Leprosy Review 60:267-273, 1989.
20. Secretaria Municipal de Saúde/Núcleo de Informação em Saúde de Uberlândia (SAUDI), 2000.
21. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273:59-63, 1996.
22. Souza CS, Alberto FL, Foss NT. Disseminated intravascular coagulopathy as an adverse reaction to intermittent rifampin schedule in the treatment of leprosy. International Journal of Leprosy 65:366-371, 1997.
23. a Edição, 1997.
24. o Edição, p. 61, 1995.
25. Yawalkar SJ. Leprosy. Ciba Geigy Limited, Basle, Switzerland. p.132, 1992.